Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

Anti-dumping probes rise with green shoots
Even as the economy is showing signs of revival, industry"s fears about dumping by other countries is on the rise, prompting the government to initiate as many as 20 fresh anti-dumping investigations since the beginning of current financial year, compared to 21 in all of 2008-09.

RBS to get virtually nationalised; govt to hike stake to 84%
The British government is planning to pump in an additional capital of up to 19 billion pound into the Royal Bank of Scotland (RBS) and hike its stake to as much as 84 per cent, a move that would virtually nationalise the bank.

News of the day

Coal India initiates dialogue for IPO
Coal India today said it has initiated dialogues with the government for its initial public offer and the navratna PSU could be listed soon as the market scenario has turned favourable.
Business Ideas

Glenmark's drug fails clinical trials

Glenmark Pharmaceuticals (Switzerland), a subsidiary of Glenmark Pharmaceuticals India (GPL) said that its molecule under development Oglemilast has failed to yield positive results in clinical trials for Chronic Obstructive Pulmonary Disease (COPD), an acute form of smoking induced lung disease. - Glenmark faces patent infringement case in US - Glenmark confirms Smithkline's lawsuit in US - Glenmark gets US nod for ointment - Glenmark gets US regulatory nod for anti-hypertension tablets - Glenmark to stop morphine sales in US - Aurobindo gets FDA nod for anti-depression drug The company had licensed the potential drug to US-based Forest Laboratories, who was conducting clinical trials to develop the drug for COPD and asthma. “Oglemilast is an orally administered PDE 4 inhibitor, which we believe to be an important and novel therapeutic target for COPD. We are, of course, disappointed that Oglemilast has not been successful in this study,” said Howard Solomon, Chairman and Chief Executive Officer of Forest Laboratories. This molecule is also undergoing trials to check if it can be useful in treating asthma. "The results are expected during the first calendar quarter of 2010. We are considering together with Glenmark what further action would be useful or appropriate," said Solomon.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009